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Purpose: The present work investigates the impact of intrafraction motion of the chest 
wall due to respiration on Post Mastectomy Radiotherapy (PMRT) with TomoTherapy. The 
hypothesis of this work is that the impact of intrafraction motion on TomoTherapy PMRT will 
be insignificant as (1) the largest intrafraction movement of the chest wall (CW) in the medial-
lateral, anterior-posterior, and superior-inferior dimensions will not exceed 1 cm and (2) that 
95% of in-vivo CW point doses on the patient surface will be within 5% of calculated dose and 
all doses within 10% of calculated dose. 
Methods: 4DCT scans were acquired and intrafraction motion of the CW near 
mastectomy scar was analyzed for 5 PMRT TomoTherapy patients. In-vivo patient CW dose 
measurements, acquired for clinical purpose using TLD were analyzed. Measured dose was 
compared to the TomoTherapy calculated dose. Daily MVCT images were collected and the 
correlation between the amount of air cavity between CW skin and the bolus and the dose 
difference between TLD measured and calculated dose was studied for each patient. Surface 
dose measurement using a CW anthropomorphic phantom was performed to add confidence to 
the patients’ data. 
Results: The maximum anterior posterior (ant-pos) CW movement of our five patients 
did not exceed 0.15 cm. 28% of the TLD measured doses differed from the calculated dose by 
more than 5%, and 2% of all data differed from the calculated dose by more than 10%. Slight 
positive correlation between air cavity between bolus and the CW surface and measured dose 
difference was observed for both patients’ and phantom data. 
xii 
 
Conclusions: The result of this work indicates that the impact of intrafraction motion on 
TomoTherapy PMRT will be insignificant. Discrepancies between TLD measured CW point 
dose and calculated dose, but overall, the average dose differences were within 5%. Air cavities 







I.    Background and Significance 
 




Breast cancer is the most commonly diagnosed non-dermatologic cancer and the second 
leading cause of cancer-related death among women in the United States. The American Cancer 
Society estimated that 182,460 new cases of invasive breast cancer would be diagnosed among 
women, and approximately 40,480 women were expected to die from breast cancer in 2008. 
(American Cancer Society Inc. 2007-2008) Primary therapy for breast cancer generally involves 
lumpectomy and radiotherapy or modified radical mastectomy. Post mastectomy radiotherapy 
(PMRT) refers to comprehensive treatment of the chest wall and appropriate draining regional 
nodes. The rationale for PMRT is to improve overall survival and prevent recurrence of cancer in 
the chest wall, skin, mastectomy scar, and the regional nodes such as the axillary, supraclavicular 
and internal mammary nodes. Mastectomy followed by radiation therapy alone could result in 
long-term control of disease, even in patients with locally advanced breast cancer. (Strom et al 
1991) Recent studies show a significant improvement in survival after PMRT in patients who 
received systemic therapy. (Overgaard et al 1997, Overgaard et al 1999) On the basis of these 
studies, a National Institutes of Health consensus panel recommended locoregional PMRT in 
patients with ≥ 4 positive axillary lymph nodes and/or T3 and T4 staged lesions. (Eifel et al 
2000) A dose of 50 Gy in 25 fractions is usually prescribed. 
2. Conventional PMRT Techniques 
 
The complexity of PMRT in treating chest wall and regional nodes often poses many 
challenges to the radiation oncologist as the range of body habitus and close proximity of the 
internal mammary nodes (IMNs) to the heart often necessitate individualized treatment planning 
2 
 
with complex field arrangements. No single technique is accepted as a gold standard. Pierce et al. 
(2002) performed plan comparisons for 20 left-sided PMRT chest wall patients. Seven 
commonly used conventional techniques were planned for each patient, using a prescription of 
50 Gy in 25 fractions to the chest wall (CW) and IMN targets. Radiationtherapy (RT) techniques 
(c.f. Figure 1.1) planned were: (1) standard tangents; (2) electron fields; (3) cobalt fields; (4) 
reverse hockey stick (RHS); (5) 30%/70% Photon/Electron mix; (6) 20%/80% Photon/Electron 
mix; and (7) partially wide tangent fields (PWTF). Diagrammatic presentations of seven RT 
techniques are shown in Figure 1.1. Dosimetric comparisons for the seven techniques were made 
using normal tissue complication probability prediction for pneumonitis and ischemic heart 
disease and dose-volume histogram analyses for normal and target issues. The study concluded 
that no one technique studied combined the best CW and IMN coverage with minimal lung and 
heart complication probabilities. Of the seven techniques studied, however, the use of PWTF’s 
was found to produce the most appropriate compromise of PTV coverage and normal tissue 
sparing. In conclusion, the study recommended that the final selection of an RT technique should 
be based on the estimated risk reduction in locoregional recurrence and its potential impact on 
survival, the predicted complication risk for the patient, and the technique expertise available to 
implement complex treatment plans. (Pierce et al 2002) The study took neither IMRT nor 





The TomoTherapy Hi-ART System® (TomoTherapy Inc., Madison, WI) is a radiotherapy 
machine designed to deliver intensity modulated radiotherapy (IMRT) using helical tomotherapy 




Figure 1.1. Diagrammatic presentation of RT techniques (Pierce et al 2002) 
 
(Mackie et al 1993) The basic configuration of the TomoTherapy unit is illustrated in Figure 1.2. 
The source of radiation is an unflattened 6 MV x-ray beam produced by an in-line linear 
accelerator (linac) mounted on a continuously rotating CT-style ring gantry with a bore diameter 
of 85 cm. The beam is collimated to a fan beam that is 40-cm wide by 1.0, 2.5, or 5.0 cm long, 
defined by a pair of x-ray jaws.  
 During treatment, the rotating fan beam radiation is delivered to the patient while the 
couch moves through the gantry in a longitudinal direction, resulting in a helical delivery pattern. 
(c.f. Figure 1.3) Intensity modulation is achieved by a 1-D multi-leaf collimator (MLC) with 64 
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binary leaves for which each leaf position is either open (i.e., letting the beam pass through) or 
closed (i.e., blocking the beam). The leaf width is 0.625 cm at isocenter.  
 
Figure 1.2. Picture of TomoTherapy unit. Linear accelerator is mounted to a gantry with a bore 
diameter of 85 cm. The axis of rotation is also 85 cm from the x-ray target source. 
 
 












Non-uniform beam intensity is achieved by varying the leaf opening time. A beamlet is 
defined as that portion of the radiation beam defined by one projection angle and one open MLC 
leaf (e.g. 0.625 cm x 2.5 cm). During beamlet optimization, beam weight is optimized for 51 
gantry mini arcs (7.06°) or projections per gantry rotation, making a total of 3,264 possible 
beamlets in each rotation. The large number of incident beam angles (51) and beamlets (3,264) 
allows delivery of highly conformal dose distributions. The total number of possible beamlets is 
3,264 x number of gantry rotations, n,  given by 
 
when pitch is defined as the ratio of the couch travel distance per rotation to the field size defined 
at the axis. Kissick et al. (2005) studied the helical tomotherapy thread effect and determined that 
a pitch of 0.86/n, when n is on integer, will minimize the ripple. (Kissick et al 2005) A pitch of 
0.287 (0.86/3) is typically used at MBPCC.  
The other unique capability of the TomoTherapy Hi-Art is its real-time imaging system. 
A conventional xenon ion chamber CT detector system is located 180˚ from the treatment linac. 
The detector reads the amount of exit radiation as the beam passes through the patient and the 
couch. The collected megavoltage transmission data is used for generating MVCT images for the 
patient registration (Fitchard et al 1998a, Fitchard et al 1998b, Lu et al 1999) and potentially for 
dose reconstruction (McNutt et al 1996a, McNutt et al 1996b, Olivera et al 1998). In 
TomoTherapy MVCT, the linac energy is reduced to a nominal energy of 3.5 MV. Because of 
this fairly high energy when compared to a regular kilovoltage CT (kVCT) scan, the image 




2. TomoTherapy as a Superficial Treatment 
 
Typically, IMRT has been used to treat deep-seated lesions such as lung, head and neck, 
and prostate cancer. However, recent studies have shown that TomoTherapy IMRT (helical 
tomotherapy) may be a viable alternative to treat superficial lesions that have been traditionally 
treated with electrons, static photon beams, or a combination of the two. 
Orton et al. (2005) compared TomoTherapy and conventional linac-based technique 
plans for total scalp irradiation. Their results showed improved critical structure dose and more 
homogeneous target dose with TomoTherapy plans compared to the traditional linac-based 
electron-photon technique of Tung et al. (Tung et al 1993). Dosimetric and in-vivo dose 
verification studies were performed to evaluate the efficacy of utilizing TomoTherapy to treat 
anal adenocarcinoma patients who have undergone abdominoperineal resection. (Han et al 2008) 
In their study, TomoTherapy plans were compared to step-and-shoot IMRT technique plans. 
TomoTherapy plans showed significantly better target dose homogeneity and dose conformity 
around the PTV. Diode-based dose measurements on the surface of the scar located in the 
perineal area and the anterior surface of the external genitalia area all showed reasonable 
agreement (-3.4% to 5.5%) with the calculated dose.  
Craniospinal irradiation has been traditionally treated using static parallel opposed photon 
beams for the brain and base of brain and using static posterior field(s) of electron (children) or 
photon (adult) beam for the spinal theca. (Maor et al 1985) However, the traditional technique 
has inherent dosimetric variations due to field abutment and requires multiple room entries and 
couch/gantry rotation. Tomblyn et al. (2007) compared dose plans of a linac-based conventional 
craniospinal irradiation technique to that delivered by TomoTherapy. The TomoTherapy 
technique resulted in superior PTV dosimetry, with a higher minimum dose and better dose 
conformity. Maximum doses to normal tissues were lower compared to the traditional linac-
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based technique. Another comparison by Lee et al. (2007) showed that TomoTherapy was 
comparable to segmented multi leaf collimator (sMLC) delivery for the treatment of parotid 
gland tumors. The general conclusions of their paper is that TomoTherapy is an attractive 
alternative to conventional fixed beam techniques because (1) it minimizes field abutment issues 
and (2) it offers equal or superior dose distribution  (uniform PTV dose and less dose to critical 
structures). On the down side, TomoTherapy indicates a greater volume of low dose that could 
have implications for secondary cancers. 
For TomoTherapy to be used effectively to treat superficial lesions, it is essential that the 
treatment planning system (TPS) accurately calculate doses at or near the skin surface. Cheek et 
al. (2006) evaluated superficial dose calculations using a cylindrical film phantom. The phantom 
included removable transverse and sagittal film cassettes as shown in Figure 1.4a. TomoTherapy 
treatment plans were developed for three superficial PTVs (2, 4, and 6 cm deep radially by 90° 
azimuthally by 4 cm longitudinally). A treatment planning image of the 2 cm thick PTV is 
shown in figure 1.4b. The superficial plans were measured with Kodak (Eastman Kodak Co., 
Rochester, NY) EDR2 film and compared to the calculated dose distribution.  
Results showed that the TomoTherapy TPS algorithm overpredicted the dose in the 
surface region (depths less than 1 cm) by as much as 9.5% of the prescribed dose. At depths 
greater than 1 cm, calculated and measured dose distributions agreed within 5% in the high-dose, 
low dose-gradient region and within 2 mm distance-to-agreement (DTA) in the high-dose 
gradient region. Figure 1.5 shows the depth dose comparisons for the 4 cm PTV. It is seen that 
the fluctuations are greater for the TomoTherapy calculated doses than the measured dose. These 
differences in the surface region may be due to (1) the discretization of the dynamic delivery and 
the heavily weighted surface pencil beams and (2) failure of the convolution/superposition 
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                    (a)                (b)     
 
Figure 1.4. Pictures of (a) 13.5-cm radius by 37.4-cm length white opaque high-impact 
polystyrene cylindrical phantom is depicted with axial and sagittal film cassettes removed from 
the phantom and (b) TomoTherapy treatment planning image showing the 2 cm thick PTV, 
avoidance, blocking, and couch contours. (Cheek et al 2006) 
algorithm to account for reduced backscatter dose for highly oblique beam near the surface. 
Therefore, Cheek et al. (2006) recommended for clinical use that 1 cm of bolus be used on the 
patient surface to ensure that regions of dose inaccuracy greater than 5% underdose occur in the 
bolus, not in the target. 
At MBPCC, PMRT TomoTherapy patients are treated with an approximately 1-cm thick 
Aquaplast RT® Bolus (Radiation Products Design, Inc., Albertville, MN), which produces a rigid 
shell around the patient. This not only ensures a greater accuracy in the calculated dose, but it 
also makes it possible to expand the PTV into the bolus to minimize the dosimetric effects of 
intrafraction (e.g., respiration) and interfraction motion (e.g., setup error), although expanding 
the PTV has a negative impact with normal tissue and lung receiving more dose unless bolus is 





3. TomoTherapy as a PMRT Treatment 
 
Ashenafi et al. (2006) compared TomoTherapy plans to conventional electron-photon 
mixed beam technique plans commonly used at Mary Bird Perkins Cancer Center 
for 5 PMRT patients. Plan comparisons were based on physician clinical judgment, 
 
Figure 1.5. Comparison of TomoTherapy calculated with measured mid-arc depth dose 
curves for the 4 cm radially thick PTV. (Cheek et al 2006) 
 
dosimetric values, and biological indices. In the study, the radiation oncologist rated four 
TomoTherapy plans superior to the conventional electron/photon beam treatment plan and one 
marginally superior and  TomoTherapy was able to reduce high dose to the ipsilateral lung and 
heart, while delivering a more uniform dose distribution to the target volume. However, the 
TomoTherapy plans showed an increased risk for secondary cancer due to the contralateral 
breast, lung, and other normal tissue outside the target receiving an increased volume of low 
radiation dose.  However, the treatment plans studied were planned on static patient CT data 




4. Previous TLD Dose Verification Study 
 
After the initial TomoTherapy PMRT treatment, our radiation oncologist observed that 
the skin reaction of the PMRT patients treated with TomoTherapy appeared less severe than they 
were accustomed to seeing with conventional techniques. Based on this concern, the physician 
began requiring in-vivo TL dosimetry as a quality assurance procedure to compare measured and 
TPS calculated dose. On the first day of treatment, a radiation therapist marked a point on the 
CW near the mastectomy scar. TLD LiF powder (~45mg) in a cellophane wrapper, as shown in 
Figure 1.6(a), was taped onto the mark prior to MVCT registration, and the TLD position was 
photographed as shown in Figure 1.6(b). Upon completion of the fraction delivery, the TLD was 
removed. Calibration TLD’s were exposed on the same treatment day on a 6MV linac for four 
different doses (100, 150, 200, and 250 cGy) that bracketed the daily fraction dose. The TLDs 
were read out, and the resulting thermoluminescence (TL) counts were converted to doses. In the 
Pinnacle3 (v. 7.4f) TPS (Philips, Madison WI) TPS, a point of interest (POI) was added where 
the TLD was located by comparing the patient pictures and 3D skin rendering, as shown in 
Figure 1.6(c). The calculated POI dose was determined and compared to the TLD measured dose.  
           
           (a)                                      (b)                                                  (c) 
 
Figure 1.6. Pictures of (a) Sample TLD packet (LiF powder enclosed in a cellophane wrapper) 
used in measurements; (b) patient  with TLD packet taped on the CW near the mastectomy scar; 
(c) 3D skin rendering with POI corresponding to the location of the TLD. The scar is contoured 





The prescription dose, the calculated dose from the treatment planning system, the mean 
(±σ) measured TLD dose, and the percentage difference between the calculated and measured 
doses for each of 9 TomoTherapy PMRT patients are shown in Table 1.1. Plots of the calculated 
and the mean measured TLD doses versus fraction number for each of the 9 patients are shown 
in Figure 1.7 (a-i).  The number of TLD measurements acquired throughout the course of 
treatment ranged from 5 to 25 per patient. Overall for the 9 patients, the TLD measured 
(delivered) dose was less than the calculated (TPS) dose by 4.0 % and the standard error of the 
mean was 4.7 %. This result raised a clinical concern since some patients were underdosed by 
more than 5 %. However, two patients (cf. Fig 1.7c and 1.7f) showed an underdose by 8.5 % and 
12.2 %, respectively, with the other 7 patients showing the TLD measured (delivered) dose was 
less than the calculated (TPS) dose by 1.9 % and the standard error of the mean was 0.9 %. 
Table 1.1.  Prescribed, calculated, mean TLD measured doses for a point on patients CW, % 
difference was obtained by 100 x (measured dose – calculated)/calculated. The number of 
sample points (N), mean (Davg), and standard deviation of the mean (σ) are given for each patient. 
(Fx: fraction) 
 
   Prescribed Calculated Measured Difference
  Doses Doses Doses 
Patient fxs[#] fx Dose[cGy] [cGy] N Davg ± σ [cGy] [%] 
1 30 220 230.2 14 224.4 ± 13.5 -2.5 ± 5.8 
2 25 200 202.9 5 201.2 ± 8.0 -0.8 ± 4.0 
3 25 200 201.4 15 184.3 ± 11.4 -8.5 ± 5.7 
4 25 200 208.7 25 198.0 ± 8.1 -5.1 ± 3.9 
5 25 200 208.5 22 199.5 ± 8.6 -4.3 ± 4.1 
6 25 200 218.9 22 192.3 ± 8.8 -12.2 ± 8.7
7 25 200 205 23 206.1 ± 6.0 0.5 ± 2.9 
8 30 150 152 10 152.0 ± 6.5 0.0 ± 4.3 
9 25 150 151.8 21 150.3 ± 5.9 -1.0 ± 3.4 
Mean ± σ  -4.0 ± 4.7 





             (a)           (b)                     (c) 
 
 
         (d)            (e)                    (f) 
     
        (g)          (h)           (i) 
Figure 1.7. (a)-(i) Calculated doses (square) and mean measured TLD doses (diamonds) 
for 9 TomoTherapy PMRT patients. 
 
Although 7 CW patients showed good agreement between measured and calculated doses 
(-1.9 ± 0.9 %), the cause of underdosing greater than 5 % were of clinical concern. This result 
compelled additional validation of the accuracy of TomoTherapy CW dose delivery by the 
clinical physics group, as well as an investigation of the possible sources of dose variation (e.g., 
intrafraction motion of CW, air cavities created between the skin surface and bolus). 
   5.     Factors that Affect Dose Variation 
a. Intrafraction Motion 
 
Organs of the thoracic and abdominal regions are known to move with breathing. 
Previous works have observed and measured the movement of the organ and the tumor of 
different sites such as lung, diaphragm, pancreas, liver, and breast via ultrasound, CT, 4DCT, 
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MR, and fluoroscopy. (Keall et al 2006)  However, none of the studies focused on chest wall 
movement in PMRT. Since our clinicians are in the early stages of using TomoTherapy for 
PMRT and understanding the range of CW movement was desirable, physicians ordered 4DCT 
scans to evaluate chest wall motion. Also TL dosimetry to measure delivered dose on the 
patient’s skin surface was continued.  
4DCT can be accomplished by oversampling CT data acquisition for each slice 
throughout the breathing cycle. During several CT tube rotations projection data are collected in 
axial cine mode for the duration of the patient’s respiratory cycle in a fixed couch position. Our 
GE Light Speed RT (SN 55011) can scan 16 simultaneous axial images of 2.5 mm slice 
thickness, which means a 4 cm body section (16 x 2.5 mm) can be scanned at one time.  Multiple 
images are then reconstructed per slice that are evenly distributed over the acquisition time.  
After data acquisition at one couch position is completed, x-rays are turned off and the couch 
advances to begin data acquisition again. This is repeated until full coverage of the scan length 
has been obtained (Rietzel et al 2005).   
For external registration, the Real-Time Position Management (RPM) Respiratory Gating 
System (Varian Medical Systems, Palo Alto, CA) was used to monitor and record respiratory 
motion based on infrared reflecting markers on the patient’s abdomen. The markers were 
illuminated by infrared emitting diodes, and images of the markers were captured by a camera at 
30 frames per second. The RPM system (marker box and camera system) in the CT room is 
shown in Figure 1.8. 
The GE Advantage 4D version 1.6 software is used to sort images into temporally 
coherent volumetric image data sets. The software reads the reconstructed images as well as the  
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(a)                                                                  (b) 
 
Figure 1.8. Pictures of (a) RPM respiratory gating system and (b) infrared emitting 
diodes surrounding a camera 
 
corresponding RPM respiratory data file. In building a spatially coherent volumetric data set, a 
specific respiratory phase has to be chosen. At MBPCC, we divide one breath cycle into 10 
equally spaced phase bins, with 0% being the inhalation peak and 50% the exhalation peak. For 
each couch position, the reconstructed image with the respiratory phase nearest the requested 
phase is selected by the GE software to form the 3D data set for a given time instant (Pan et al 
2004). Figure 1.9 shows a qualitative illustration of scan and reconstruction. In the illustration, 
there are four images reconstructed per sample for a four-slice multi-slice (MSCT) and eight 
samples in a respiratory cycle. Once sorted into phases, a CT volume is exported into DICOM 
format for each of the selected phases.  
 There are considerable concerns regarding the use of IMRT with targets affected by 
intrafraction motions. One concern is that the increased conformality of IMRT dose distributions 
can potentially lead to underdoses at the border of the target volume due to intra/interfraction 
motion. However, Yu et al. (1998) showed that fluence variations within a moving target tend to 




Figure 1.9. An illustration of scanning and image reconstruction. (Pan et al 2004) 
 
or frequency is random from day to day. An investigation of TomoTherapy beam delivery 
suggested that the dose variations caused by intrafraction respiratory motions of typical breathing 
(amplitude is smaller than 1 cm peak to peak) is minor for the helical beam with a 2.5 cm slit and 
4 rpm rotational speed (Yang et al 1996). Another motion phantom study on TomoTherapy by 
Kanagaki et al. (2007) focused on the dosimetric impact of respiratory motion in the 
superior/inferior dimension with varied treatment unit parameters. The study validated helical 
TomoTherapy as a safe technique for treating moving tumors given the current standard of 
margin expansion. 
Interfraction motion is also a critical issue. A variety of image-guided radiation therapy 
(IGRT) systems have been developed that allow verification and correction of the target position 
prior to each treatment.  
The utility of TomoTherapy MVCT scanning prior to the treatment fraction is 
particularly important when the patient’s anatomy may vary between fractions, as the treatment 
can be significantly degraded if changes in the patient’s anatomy are not detected (Ruchala et al 
2004). It is advantageous to have this scanning technology incorporated into the therapy machine, 
so that the patient need not move between the CT scan and the treatment delivery. Because of 
this feature, interfraction movement can be minimized. 
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To confidently treat PMRT patients with TomoTherapy, it is important to show that 
intrafraction motions of chest wall have little impact on the dose distribution and that doses are 
delivered accurately. Intrafraction motion can be evaluated via 4DCT. Interfraction motion can 
be accounted for by acquiring an MVCT scan every day prior to the fraction delivery for PMRT 
patients. Based on MVCT, appropriate shifts can be made to align the patient’s anatomy, then 
overlay kVCT based dose distribution for final adjustment. All the MVCT data are stored so that 
dose re-computation can be performed if needed. 
b. Air Cavities 
 
The bolus is used to provide adequate dose buildup over the skin surface. In 
 
TomoTherapy PMRT, approximately 1 cm thickness of solid thermoplastic bolus (Aquaplast 
RT® Custom Bolus, WFR/Aquaplast Corp.) is used. The bolus is molded to fit the patient’s CW 
contour by a technician prior to the planning CT acquisition. Also, having the patient scanned 
with bolus allows the expansion of the PTV above the skin without having a negative impact on 
the optimization of beamlet fluence patterns near the skin. When constructing the bolus, it is 
important to leave minimal air cavities between the bolus and the patient CW. The air cavities 
between the absorber and the surface could result in electronic disequilibrium and decreased 
dose to the CW.  
Based on clinical experience at MBPCC, throughout the typical PMRT CW treatment 
course of 5 weeks, the bolus tends to dry and shrink, which slightly change its shape, likely 
increasing air cavities between the bolus and patient skin surface. Figure 1.10 shows an example 
of increasing air cavity as the treatment progresses (fraction 11 vs. fraction 25) on patient 3, from 
previous TLD dose verification study, whose averaged measured dose was 8.5% lower than the 
calculated dose from our previous TLD study. Obese patients tend to exhibit more severe 
irregularities in skin surface, and the amount of air cavities created is significant enough to result 
17 
 
in dose deficit. This is not taken into account upon planning since there are no air cavities at a 
time of CT acquisition. The size of air cavities depends on each patient’s surface anatomy, set-up 
parameters, and how much the bolus changes in shape. It is extremely difficult to combine all 
these effects and predict the dose distribution. However, with the existing daily MVCT data sets 
and in-vivo TLD measurement data, we may be able to investigate the dose around the 
superficial regions of air cavities. 
  
Figure 1.10. MVCT images of patient 3 taken prior to the treatment at (a) fraction 11 compared 
to (b) fraction 25 which increase of air cavity is observed. Light blue cross is where TLD 
package was taped. 
 
  The purpose of the present study is to study in-vivo TL dose measured data for patients 
treated using TomoTherapy for PMRT and to investigate possible sources of dose variation from 
planned dose distribution such as intrafraction motion and air cavities. 
II.   Hypothesis and Specific Aims 
       A.  Hypothesis 
Impact of intrafraction motion on TomoTherapy Post-Mastectomy Radiotherapy (PMRT) 
will be insignificant as (1) the largest intrafraction movement of the chest wall (CW) in the 
medial-lateral, anterior-posterior, and superior-inferior dimensions will not exceed 1 cm and (2) 
that 95% of in-vivo CW point doses on the patient surface will be within 5% of calculated dose 




       B.   Specific Aims 
Aim 1. Characterize intrafraction motion of patients 
Clinically acquired 4DCT and 3DCT scan data for 5 CW patients will be analyzed and 
intrafraction motion will be determined. 
Aim 2. Analyze clinical dose measurements at multiple points during treatment and 
compare with calculated dose: 
 Clinical TLD data for 5 CW patients, acquired for 15 fractions, will be compared with 
calculated dose.  
Aim 3. Measure surface dose at multiple points on phantom and compare with calculated 
dose: 
 TLD measurement data for anthropomorphic CW phantom will be compared with 


























Methods and Materials 
 
I.    Aim 1 
 
The purpose of aim 1 was to characterize intrafraction CW motion of TomoTherapy 
patients. The 3DCT and 4DCT scan data for 5 CW TomoTherapy acquired for clinical purposes 
with a GE LightSpeed RT were analyzed in this study.  The static 3DCT scan was used for 
treatment planning, and the 4DCT scan was used to evaluate chest wall motion due to breathing.  
      A. Clinical CT Simulation 
 1. Patient Marking 
Prior to clinical scanning, a Vac-Loc (Civco Medical Solutions, Kalona, Iowa, USA) 
immobilization cushion was fabricated to ensure daily setup reproducibility on the TomoTherapy 
unit. Shown in Figure 2.1(a), the mastectomy scar was marked with a CT-SPOTS® line marker 
(Order code #118 Beekley Corp.) by a CT technologist. Once the scar was marked, 7-8 points 
surrounding the scar were marked with a permanent marker with uniform spacing approximately 
every 3-cm. A 2.3-mm diameter CT-SPOTS® pellet (Order code #120 Beekley Corp.) was 
placed on each of the points, as shown in Figure 2.1(b). These markers were used in the 4DCT 
images to assess chest wall motion throughout the breathing cycle. 
2. Immobilization and Skin Bolus 
      At MBPCC, every PMRT TomoTherapy patient is treated with 1-cm thickness bolus, 
which serves two purposes. The first purpose is to provide charged particle equilibrium at the 
skin surface ensuring that the chest wall and scar receive the prescribed dose. The second 
purpose is to allow for the expansion of the PTV outside of this skin surface to account for chest 
wall motion and setup uncertainties. A solid thermoplastic bolus (Aquaplast RT® Custom Bolus, 
WFR/Aquaplast Corp.)  was placed into hot water (~160 ºF) bath and allowed to soften. After 
the bolus was removed from hot water bath, the CT technologist molded the bolus to the 
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                      (a)                                                                     (b) 
Figure 2.1. Picture of (a) CT-SPOT®  pellet and (b) patient CW with intrafraction movement 
points marked. CT-SPOT®    line marker was placed to trace the mastectomy scar.  
 
patient’s CW ensuring it covered the entire expected PTV. Unnecessary bolus was cut off, laser 
alignment marks were drawn on the bolus, one near sternum and another one on lateral side. An 
example of the bolus with reference marks is shown in Figure 2.2.  
B. CT Scan Acquisition  
Once the pre-scan procedures were completed, the 3D scan was performed according to 
the institution’s clinical scan protocol. The 3D scans for the patients, whose data is used in the 
present study, were taken at 120 kV and 80 mA. 
The 4DCT dataset for the same patient was used strictly to evaluate the magnitude of 
chest wall motion throughout the breathing cycle to ensure that adequate PTV expansion was 
used. The 4DCT scan was acquired according to our in-house 4D scanning protocol.  
To reduce unnecessary radiation dose to the patients, the scan range was limited to the 
volume including the CT-SPOTS pellets plus an approximately 2-cm margin inferiorly and 
superiorly to cover the projected maximum pellet travel when setting the cine scan range. 






Figure 2.2. Picture of PMRT patient with bolus on right chest wall. Laser alignment marks in 
cross hair is drawn on the bolus, which indicates the patient will be aligned to match the 
marks with laser in the treatment room prior to their treatment.  Vaclock immobilization 
device was fabricated to stabilize patient’s right arm up in place.   
 
C. Transferring CT Data 
TomoTherapy PMRT planning was done on 3DCT images. By default, the TomoTherapy 
DICOM server down samples the CT images to 256 x 256 matrix. However, this is often too 
many data points for the optimizer to perform a beamlet optimization without error. MBPCC 
policy states that TomoTherapy patient plans will be planned using the finest dose grid and 
resolution available, but if that is not possible, the CT image resolution should be down sampled 
(reducing the matrix size, thus resulting in volume averaging of the CT data and reducing spatial 
resolution) prior to planning. Since our clinical standard for planning PMRT is to down sample 
the CT image resolution to 128 x 128 matrix in order to avoid any optimization error, the 
phantom image was down sampled accordingly. Hence, down-sampled CT scan data was 
imported into the TomoTherapy treatment planning system from the CT workstation (GE 
Discovery DT,) after the 3DCT scan was acquired. Regarding 4DCT data, the RPM files and 
4DCT images were transferred to the Advantage Workstation® (AW) where images were sorted 
22 
 
into 10 different respiratory phases. CT data for each of the selected phases were exported in 
Dicom format and then imported on Pinnacle Treatment Planning System (TPS). 
D. TomoTherapy PMRT Treatment Planning 
PTVs, which included chest wall (CW), and regional lymph nodes such as the 
supraclavicular (SC), the internal mammary chain (IMN), and the axillary (AX) nodes, were 
contoured by our radiation oncologist (Renee Levine, MD) on the Pinnacle TPS for all five 
patients. For these patients, the PTV included the bolus to account for intrafraction breathing 
motion during treatment and for interfraction setup errors. Additionally the PTV extended 
approximately 5-mm into the lung, again to allow for intrafraction motion. A typical axial 
contour including the  PTV is shown in Figure 2.3. ROIs were transferred from the Pinnacle 
workstation to the TomoTherapy TPS for treatment planning. 
 
 
Figure 2.3. PTV is contoured in red line. Scar is shown in orange area. 
 
The TomoTherapy TPS was used to generate an IMRT plan for each patient. The 
doseprescription was 50 Gy in 25 fractions (200 cGy/fraction) for all patients. All treatment 
plans in this study were performed by a board certified dosimetrist (Eddie Singleton,CMD) to 
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reduce planning variations. The plan parameter values used for treatment planning were: field 
width = 2.45 cm; pitch = 0.287, planning modulation factor = 3.00, dose grid resolution = 
‘normal’ 
E. Characterizing Intrafraction Chest Wall Motion 
 
To characterize intrafraction chest wall motion over all phases of the patient’s breathing 
cycle, each CT-SPOT®  pellet placed during 4DCT scan was analyzed for maximum movement 
in the medial-lateral, anterior-posterior, and superior-inferior direction. In Pinnacle, the pellets 
placed around the patients mastectomy scar were identified on each phase image set of the 4DCT, 
and a POI was added at the location for each pellet. A sample 3D skin rendering showing the 
skin surface POIs and scar is shown in Figure 2.4(a). A photo showing the actual marker and 
scar position at the time of CT acquisition is shown in Figure 2.4(b) for comparison.   
 
                (a)                                                               (b) 
Figure 2.4. Image (a) of 3D skin rendering showing POIs as white dots on skin surface. Scar 
contoured and shown in yellow. Picture (b) of the actual CT-SPOT® pellet placements on patient. 
Figure 2.5 shows the 3D skin rendering of 5 patients (A-E) with 6 to 8 different colored 
spheres representing the placement of radiopaque pellets taped prior to their scan. The spheres 
are for visualization purposes and not to scale. Mastectomy scars are shown in purple.  
Once a POI was added, its location in the AP, SI, and lateral directions was located in the 
CT coordinate system. Figure 2.6 shows the sample location of a single marker at each phase of 
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the breathing cycle. The arrow points to the marker and the CT coordinates are shown in the 
lower left corner of each image.   
To numerically analyze marker movement, the coordinate at each phase was recorded. 
For each pellet, the maximum separation was determined from the maximum spread of each 
coordinate over all ten breathing phases. The overall intrafraction chest wall motion of each 
patient was taken to be the largest marker displacement over all phases of breathing.  
II.    Aim 2 
 
        Aim 2 was to analyze clinical CW dose data at multiple points during treatment for 
comparison with calculated dose. CW point doses measured with TLD for 5 TomoTherapy 
PMRT patients (Patient A-E). TLD measurements were repeated every fraction for the first week 
then every other fraction after that to collect 15 data sets total. Their mean region of interest 
(ROI) dose was obtained from Pinnacle TPS and the TLD measured dose was compared to the 
calculated dose. A treatment verification MVCT scan was acquired prior to the daily treatment 
and their data was transferred to Pinnacle TPS to study the air cavity created between bolus and 
the CW surface.  
A.   Chest Wall TLD Measurements 
1.   Measurement Conditions 
Each TL dosimeter contained LiF TLD-100 powder sealed in a cellophane packet. Each 
packet contained approximately 45-mg of powder in an approximately 1 x 1 x 0.2 cm3 volume, 
spread to create an approximately even layer. Of the multiple pellet points used to evaluate chest 
wall motion, 3-4 locations were selected as TLD positions to measure delivered dose. For some 
patients, an additional TLD mark was added at the midpoint of the scar on the first day of the 
treatment. Setup photos showing the location of the TLD placement were taken and compared 






Figure 2.5.  3D skin rendering images of patients A through E with 7-8 spheres 
representing the location of radiopaque markers displaced on surface.  
Patient A 





























Figure 2.6. Tracking of the marker movement at each stage of breathing cycle and their 
coordinate recorded. 
 
2. Patient TLD Irradiation 
At the beginning of the each daily treatment, prior to MVCT scan, one TLD packet was 
taped on each mark. Then, patients were aligned to their reference marks and the bolus was 
placed on the chest wall. Each daily MVCT scan was performed using coarse slice thickness (6 
mm) to reduce the scanning time. Once the MVCT image was acquired, the image registration to 




Figure 2.7. Placement of In-vivo TLDs for Patient A: (a) Patient photo showing the location of 








Figure 2.8. Placement of In-vivo TLDs for Patient B: (a) Patient photo showing the location of 












Figure 2.9. Placement of In-vivo TLDs for Patient C: (a) Patient photo showing the 







Figure 2.10. Placement of In-vivo TLDs for Patient D: (a) Patient photo showing  












Figure 2.11. Placement of In-vivo TLDs for Patient E: (a) Patient photo showing  
location of the TLD placement and (b) 3D rendering image of the same patient from 
Pinnacle TPS. 
 
automatic registration software. After that, the registration was manually adjusted giving 
preference to particular regions of interest (e.g., PTV). Additionally, the dose distribution 
(calculated on the planning CT data, not the daily MVCT) was evaluated to ensure adequate 
coverage of the PTV. Once the final registration was accepted, patients were re-positioned based 
on their calculated shifts and treatment was delivered. Once the treatment was completed, the 
bolus was removed and the TLD packets were collected for readout. 
3. TLD Calibration 
Calibration TLD packets were irradiated to known doses (100, 150, 200, and 250 cGy) 
that encompassed the expected daily fraction dose of 200 cGy. The TLDs were placed at 100 cm 
SSD at a depth of 1.5 cm in Plastic Water® on a Novalis BrainLab 6MV beam. Ten centimeters 
of Plastic Water® was used beneath the TLD packets to provide backscatter. One packet was not 
irradiated to determine the background signal. All the TLD packets were kept in dark over night 
to be read the next day. TLD’s were calibrated every day and used to determine the measured 








time between exposure and readout since the time difference (approximately 24 hours) was 
approximately the same for the calibration and experimental TLD’s each day.  
4. Reading of TLDs and Conversion to Dose 
The TLD samples were read using a REXON UL-320 Reader (Rexon Components, Inc.). 
An analytical balance (AL54, Mettler-Toledo, Inc.) was used to measure the mass of each 
powder sample that was read. The TLD powder in each packet was divided into 3 approximately 
equal samples (≈15mg each) to reduce uncertainty in the mean TL and thus dose value. The 
empty planchet was placed on a scale and weighed, then the balance was rezeroed to remove the 
planchet mass before the measurements were taken. For each sample, the thermoluminescence 
(TL) or the photon count from the peak of the glow curve (135°C to240°C) was recorded along 
with the mass of sample,  allowing determination of samplemassTL )/(  . A net TL per mass, 
netmassTL )/( , was found by subtracting the mean TL per mass of the background TLD sample, 
bkgmassTL )/( , from the TL per mass of the sample, samplemassTL )/( .  
The calibration curve was obtained by determining the netmassTL )/(  for each of the 
calibration doses.  Sample TLD calibration data and fit is shown in Figure 2.12. For each calibration 
dataset, a linear fit was applied to the data, and sample doses were determined using the fit curve. 
Extrapolation was not needed, as the range of calibration doses encompassed the range of 
measured patient doses. The three samples of each packet were used to determine the mean dose 
and standard deviation of the mean for each TLD packet.  
      B. Obtaining Calculated TLD Doses 
The TomoTherapy dose plan was exported to the Pinnacle TPS for determination of the 
calculated TLD doses. A region of interest (ROI) was added for each TLD packet at its location 
on the patient, as identified by the pellet’s in the CT scan. The CT slice containing the center of 
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Figure 2.12. Sample TLD calibration data and fit 
each pellet was located, and an ROI approximately 0.1 x 1 cm2 was drawn centered on the pellet 
and on the surface of the chest wall, as seen in Figure 2.13(a). The ROI was copied to next two 
slices superiorly and inferiorly to approximate the physical size of the TLD packet. Average ROI 
dose was then obtained and compared to TLD measured doses. A sample TLD ROI and its dose 
statistics are shown in figure 2.13(b).  
C. Evaluation of Effect of Air Cavity on Delivered Dose to Skin Surface 
 
Correlation between the amount of air cavity created between thermoplastic bolus and the 
chest wall dose measured with TLD was analyzed and studied for the patients. 
1.  Importing  MVCT Data to Pinnacle 
      TomoTherapy Hi-ART® planned adaptive software (Version 2.2.1.55) was used to 
retrieve daily MVCT images of the patients and export the data to Pinnacle. MVCT images were 
then compared with planning CT images to determine the location of the marker used for TLD 
placement. MVCT window and level were changed to default lung setting so that the air cavity 
between bolus and skin was clearly seen. Coarse resolution (6 mm slice thickness) was selected 
at the time of MVCT for all the CW patients. A POI was added at the location of each TLD.  
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Figure 2.13. Sample TLD (a) ROI and (b) dose statistics. Mean ROI dose was used as 
calculated dose for a comparison. 
 
placement. MVCT window and level were changed to default lung setting so that the air cavity 
between bolus and skin was clearly seen. Coarse resolution (6 mm slice thickness) was selected 
at the time of MVCT for all the CW patients. A POI was added at the location of each TLD.  
2.   Contouring of Air Cavity 
Air cavities between the bolus and the patient’s CW were contoured to obtain the air 
volumes surrounding the TLD pack. The amount of air volumes obtained were used to study the 
impact of air cavity on the chest wall doses. Air cavities within 2.5 cm of the TLD location were 
manually contoured and the total volume was obtained as shown in Figure 2.14. The thickness of 
the air cavity directly above the TLDs of air cavity above the TLD’s were also measured and 
recorded to study the correlation between air cavity size and chest wall dose. Air contours were 
performed for the five patients (A through E) as well as for the Patient 3 (Patient F) from our 








doses was 8.7%. Correlation between the air volume as well as air thickness above TLD packet, 
and TLD measured chest wall dose analyzed for data from the patients.  
 
Figure 2.14. MVCT image of patient CW with bolus placed. TLD location in orange 
circle and air cavity contour in orange line is shown. 
 
III. Aim 3 
 Aim 3 was to measure surface dose at multiple points on phantom and compare with 
calculated dose. 3 TLD measurements were performed to add confidence in our TLD 
measurements and their comparison to the calculated dose in both patient measurements and 
phantom measurements. Effect of phantom shift on delivered dose to  surface and effect of foam 
cavity between bolus and the phantom surface on phantom surface dose were evaluated by using 
anthropomorphic CW phantom and compared with patient data. 
     A.  TLD Measurements Test 
1.   Accuracy and Precision of TLD Measurements Due to TLD System 
      Measurements to test the accuracy and precision of our TLD system used in this study 
were performed. Three independent sets of measurements were taken to obtain the accuracy of 
our TLD system. Each experimental set of TLD’s were irradiated to 175, 200, and 225 cGy using 






read and the TLs were converted in doses the next day. Predicted and measured doses were then 
compared. 
  2.   Accuracy of TLD Dose Measurements in Anthropomorphic CW Phantom 
The accuracy of patient measurements depends primarily upon accuracy of TLD system, 
accuracy of TomoTherapy delivery, accuracy of the TomoTherapy treatment planning system, 
intrafraction patient motion, how well the bolus fits the patient, and possibly other patient-
dependent factors. As the present study is designed to evaluate dose inaccuracies due to patient 
effects, the present section looks at dose accuracy without such patient effects. This is done by 
comparing measured with calculated dose for an anthropomorphic Torso PhantomTM (Spect 
company info. Model ECT/TOR/P), shown in Figure 2.15(a)-(c). 
 The phantom included large, body-shaped lung, liver and spine inserts. Lung inserts were 
filled with Styrofoam® beads and water to simulate average lung tissue density. The liver insert, 
and remainder of the phantom except spine insert was filled with water. Lateral (R-L) and 
anterior-posterior outside dimensions were 38-cm and 26-cm, respectively, to simulate the upper 
torso of average to large male and female patients. The phantom wall thickness was 9.5-mm 
polymethylmethacrylate (PMMA).  
a. Acquiring CT Scan 
A scan of the phantom was acquired using the GE LightSpeed RT. To replicate clinical 
PMRT as closely as possible, mastectomy scar tape was placed laterally on the right CW surface. 
4 CT-SPOTS® pellets  (one superior, two inferior, and one in the middle of the scar) were placed, 
and locations of the pellets were marked using permanent marker for later placing the TLD prior 
to treatment delivery (c.f., figure 2.16). 
The phantom was positioned on the couch so that the CT alignment laser would intersect 
the center of the phantom. CT-SPOTS® pellets were placed at the three laser alignment marker 
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(cross-hair), one on anterior and two laterals, as indicated by the crosshairs in Figure 2.16. 
Superflab plastic bolus (Company info.) was used instead of the clinical thermoplastic bolus to 
minimize air cavities between the bolus and phantom surface, which could affect the measured 
dose.  Superflab bolus was placed on the phantom as shown in figure 2.17 and a CT scan was 
acquired with a 1.25-mm slice width. Images were transferred to Pinnacle TPS for contouring 
and to the TomoTherapy TPS for  
treatment planning. 
b.   Planning ROIs 
The Pinnacle TPS was used to contour ROIs (e.g., PTV and organs at risk, OARs). The 
PTV was drawn to cover the bolus and chest wall and to protrude into lung by more than 5 mm. 
OARs included lung, heart, spinal cord, and liver. Lung was contoured using Pinnacle’s auto 
contour tool which uses CT thresholds. Since the phantom contained no heart insert, heart 
contours had to be drawn manually by comparing with patients image of similar anatomy. Figure 
2.18 shows a CT slice with PTV contours in red, lung in green, heart in purple color wash, and 
spine in brown color wash. All the ROIs contours were evaluated and approved by a radiation 
oncologist prior to treatment planning.  
ROIs were then transferred from the Pinnacle workstation to the TomoTherapy TPS. The 
TomoTherapy TPS was used to generate an IMRT plan for the phantom. It was planned 
according to clinical procedures described in previous section.  The temporary dose distribution 
file (EOPDose.img) was saved along with the header file into a separate directory on the 
TomoTherapy workstation and subsequently exported to the Pinnacle workstation. 
c.   TLD Measurements 
Repeated CW surface dose measurements using the TLD system were taken on the 
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(c) 
Figure 2.15. Pictures of (a) superior view, (b) anterior view, and (c) inferior view of the 






                         
Figure 2.16. Picture of anthromorphic torso phantom with 4 pellets and scar tape. 
Bolus is not shown. Crosshair alignment marks are used to align phantom to isocenter 
lasers. 
 
and 1 cm thickness Superflab bolus material was used to provide adequate buildup. The PMRT 
treatment plan was delivered and TLDs packs were collected. This measurement was performed 
one day and 3 times on other day. The packs were read along with that day’s calibration TLD’s 
and converted to dose.  
To confirm our measurements, TomoTherapy Hi-ART® planned adaptive software 
(Version 2.2.1.55) was used to re-compute the dose distribution on  the phantom based on the 
MVCT image data acquired prior to the treatment delivery for each set of the measurements. 
TLD measured dose was compared with (kVCT-based) and re-computed dose (MVCT-based). 
3.   Film Measurements 
To improve confidence in our comparison between TLD measurements to calculation, the 
phantom surface dose was measured with Gafchromic® EBT film using the same setup as with 
the TLD measurements and compared with calculated dose and the previous measured TLD dose. 
They were not used as a mean of in-vivo dosimetry as the patient’s CW’s were more irregular 
than the phantom surface. An 8” x 10” film was taped onto the phantom surface to cover the  
Lateral laser cross 









Figure 2.17. Pictures of anthromorphic torso phantom with superflab bolus in place: (a) 
right-anterior-inferior oblique view and (b) inferior view. 
 
PTV as shown in Figure 2.19(a). The orientation of the film was recorded to be used for the 
image registration. The exposure included the MVCT scan and the treatment delivery. The 
measurement was repeated twice. A calibration film was exposed on the same 6MV linac as that 
used for the TLD calibration. The films were scanned the next day and the location of the TLD 
marks were identified by performing a geometric comparison. An image of the film with ruler 
tool identifying the TLD location is shown in Figure 2.19(b).  The measured dose obtained at 
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each location was compared to the corresponding TLD measurement and the difference between 
the film measured dose to the calculation was then compared with the difference between 
calculation to the previous measured TLD dose.  
 
 
Figure 2.18. ROI contours. The PTV is shown in thick red contour, lungs are shown in 
green, spinal cord is shown as brown color wash, and heart is shown as purple color wash. 
 
PTV as shown in Figure 2.19(a). The orientation of the film was recorded to be used for 
the image registration. The exposure included the MVCT scan and the treatment delivery. The 
measurement was repeated twice. A calibration film was exposed on the same 6MV linac as that 
used for the TLD calibration. The films were scanned the next day and the location of the TLD 
marks were identified by performing a geometric comparison. An image of the film with ruler 
tool identifying the TLD location is shown in Figure 2.19(b).  The measured dose obtained at 
each location was compared to the corresponding TLD measurement and the difference between 
the film measured dose to the calculation was then compared with the difference between 








Figure 2.19. Picture of (a) the phantom with film taped and (b) image of the film 
converted to dose with ruler tool locating the TLD position. 
 
B. Effect of Phantom Shift on Delivered Dose to Phantom Surface 
The purpose of the following procedure was to estimate the maximum effect of 
intrafraction motion on dose delivery. After analyzing the patient’s 4DCT data (explained in the 
previous section). It was determined that 1 cm AP chest wall motion would exceed any 
intrafraction movement expected from any PMRT patient. In fact, none of the five patient’s 
intrafraction motion exceeded 1 cm. Based on these results, the physician included a 1-cm 




Three measurements were performed using the anthropomorphic Torso PhantomTM to 
evaluate the effects of a 1-cm position offset in a treatment delivery. The first measurement was 
made with the phantom in the treatment position specified in the treatment plan. Four TLD 
packages were taped on the phantom surface, and a 1-cm thick Superflab bolus was taped onto 
the phantom. A pre-irradiation MVCT scan which showed no shift was required to align the 
phantom prior to treatment. TLD packages were collected after treatment was delivered and kept 
inside the drawer away to avoid light exposure. The second and third measurements were made 
with a couch shift. The couch was shifted 1 cm posterior from its planned position for the second 
measurement and 1 cm anterior from its planned position for the third measurement. Figure 
2.20(a) shows a setup photo of the phantom on TomoTherapy treatment couch and an illustration 
of couch shift is shown in Figure 2.20(b). The phantom remained stationary during the delivery 
as this was not a moving phantom study. 4 TLD packages and the bolus were placed on the same 
location for all the measurements. The experimental TLDs were read along with the calibration 
TLD set the next day. The results from the three measurements were compared and analyzed. 
C. Evaluation of Effect of Air Cavity on Delivered Dose to Phantom Surface 
 
Correlation between the amount of air cavity created between thermoplastic bolus and the 
chest wall dose measured with TLD was analyzed and studied for phantom measurements. 
1. Measurement of  Foam Density and Thickness 
An evaluation of the effects of air cavities on surface dose required a way to accurately 
control the air cavity under measurement conditions. Superflab was used as the bolus material in 
this study to eliminate air cavities between the chest wall and bolus. These air cavities are 
common when using the thermoplastic bolus used clinically, as it tends to shrink and deform as it 
hardens over time. Additionally, changes in patient anatomy from that occurring in the planning 
CT data set can also create air cavities.  
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                                              (a)                                                                      (b) 
Figure 2.20. (a) Setup photo of the phantom on TomoTherapy treatment couch, and (b) 
illustration of 1 cm couch shift phantom measurement. 
 
 To simulate air cavities in this study, a closed-cell foam packing material, cut into 
approximately 30x30x0.3 cm3 sheets, was used. The average thickness, as well as the density of 
each packing material was determined by measurement. The thickness was measured with a 
KANON Vernier caliper. A Mettler Electronic Analytical Balance was used to determine the 
mass of each packing sheet, which were cut to have a 10 x 10 cm2 cross section. Measurements 
were repeated 3 times to obtain uncertainty. The data, found in Table 2.1, showed a mean density 
of 0.0207±0.0014g cm-3. 
Table 2.1. Thickness and mass of foam cushioning material measured with the Vernier caliper 
and analytical balance respectively. 











1 2.98 ± 0.02 0.5753 ± 0.0001 0.0193 
2 2.60 ± 0.02 0.5714 ± 0.0002 0.0220 
3 2.78 ± 0.02 0.5791 ± 0.0002 0.0208 










2.   TLD Measurements 
The anthropomorphic phantom and plan used in the previous section were used to 
evaluate the effects of air cavities on delivered dose. Varying thicknesses of foam (0-18 mm in 3 
mm increments) were placed and taped to the phantom. Superflab bolus was then placed on top 
of the air as shown in figure 2.21. MVCT images registrations were performed to align the 
phantom prior to the each treatment delivery. Once the treatment was completed, the bolus and 
the foam sheets were removed and the TLD packets were collected, read, and converted to dose. 
Correlation between the controlled air volume, as well as air thickness above the TLD packet, 
and TLD measured phantom surface dose were then analyzed.  
 
Figure 2.21. Foam cushioning material was placed between Superflab  




















I.    Aim 1 
 
The results of intrafraction motion of radiopaque pellets for 5 patients are shown in Table 
3.1a-e. 4DCT data showed small movements < 1.5mm in lateral and anterior-posterior (ant-pos) 
directions and less than 2.5mm in the superior-inderior (sup-inf) directions were observed for all 
patients and for each marker location. Since our study is on respiratory motion, ant-pos 
movement was of primary concern. Lateral movement was small at all TLD locations for all 
patients. The smallest lateral movement was 0.02 cm at Patient E locations 1 and 2.  Sup-inf 
motion was either 0.25 cm or 0 cm as the CT slice thickness was 0.25 cm and the diameter of the 
marker was approximately 0.3 cm. The maximum patient chest wall motion data of all patients is 
shown in Table 3.1f. For each patient, the maximum displacement in each anatomic direction 
over all the markers was taken to be the intrafraction motion for that patient. Maximum ant-pos 
movements of patient A through E were 0.15 cm, 0.15 cm, 0.11 cm, 0.15 cm, and 0.06 cm 
respectively.  
II.   Aim 2  
A. TLD Measurements 
Results comparing the calculated to TLD-measured daily (fractional) doses at each TLD 
location for Patient A through E are shown in Figures 3.1 through 3.5. For each patient, dose was 
measured at four locations. For each TLD location, dose measurements are plotted versus 
fraction number for 15 of their 25 total fractions. Error bars represent the standard error of the 
mean for each dose measurement, which was obtained from three readouts of each TLD. The 
shaded region is the ±5% range about the calculated dose. Prescribed dose, calculated dose, 
average measured dose of each TLD, and the percent difference in measured and calculated 
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Table 3.1. (a) to (e) The results of intrafraction motion of radiopaque pellet markers 
for each patient. (f) A summary of our five patient’s 4DCT data 










Location [cm] [cm] [cm]  Location [cm] [cm] [cm] 
1 0.1 0.09 0.25  1 0.1 0.09 0.25 
2 0.05 0.15 0.25  2 0.05 0.15 0.25 
3 0.04 0.14 0  3 0.04 0.14 0 
4 0.09 0.07 0  4 0.09 0.07 0 
5 0.03 0.11 0.25  5 0.03 0.11 0.25 
6 0.06 0.08 0.25  6 0.06 0.08 0.25 
7 0.06 0.14 0         
                 










Location [cm] [cm] [cm]  Location [cm] [cm] [cm] 
1 0.04 0.07 0  1 0.04 0.08 0 
2 0.07 0.07 0  2 0.08 0.13 0.25 
3 0.07 0.07 0  3 0.08 0.15 0 
4 0.07 0.07 0  4 0.03 0.11 0 
5 0.1 0.07 0  5 0.04 0.14 0 
6 0.07 0.11 0.25  6 0.12 0.09 0.25 
7 0.08 0.11 0  7 0.08 0.08 0.25 
         8 0.08 0.12 0 





Inf   (f) Maximum  





1 0.02 0.04 0     [cm] [cm] [cm ] 
2 0.02 0.03 0   A 0.09 0.15 0.25 
3 0.03 0.04 0   B 0.1 0.15 0.25 
4 0.05 0.06 0   C 0.1 0.11 0.25 
5 0.05 0.08 0.25   D 0.12 0.15 0.25 
6 0.06 0.05 0   E 0.06 0.06 0.25 
7 0.03 0.06 0          
8 0.03 0.06 0          
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calculated doses for each TLD location are shown for each of  the 5 patients in Tables 3.2 
through 3.6. Percent differences were obtained from the equation below: 
                    (1) 
Patient A had 3 packets of TLD taped around the scar and one at the middle of the scar 
(cf. Figure 3.1a). Differences between TLD measured and calculated doses for Patient A are 
plotted for each TLD in Figures 3.1b-e. Small variations in the measured dose were observed 
over the course of treatment, but 70% of the measured dose was within 5% of the calculated dose 
at all TLD locations. A summary of the comparisons is shown in Table 3.2, TLDs 1 and 4 were 
positioned adjacent to each other and both agreed well, being 1.5% low and 1.1% high, 
respectively. TLDs 2 and 3 were positioned medial, lateral and slightly inferior to TLDs 1 and 4 
and slightly inferior. Their readings were 2.7% high and 3.7% low, respectively. Overall, results 
are well within the standard criteria for delivered dose accuracy of 5%. 
Table 3.2. Prescribed, calculated, mean TLD measured dose, and Dose difference between 
calculated and measured doses of patient A. 
 
  Prescribed Calculated Measured Differences
  Doses Doses Doses 
TLD fxs [#] fx Dose [cGy] [cGy] N D ± σD  [cGy] Δ ± σΔ [%] 
1 25 200 204 15 203.2 ± 5.3 -0.4 ± 2.6 
2 25 200 210.5 15 216.1 ± 9.1 2.7 ± 4.3 
3 25 200 206.7 15 199.1 ± 8.6 -3.7 ± 4.1 
4 25 200 204.8 15 207.0 ± 8.1 1.1 ± 4.0 
 
Patient B’s TLDs were placed similarly to patient A’s TLDs. TLD 1 was placed superior to the 
scar, TLDs 2 and 3 were placed lateral, medial and inferior to the scar, respectively, and TLD 4 
was placed on top of the scar (cf. Figure 3.2b). Differences between TLD measured and  
47 
 


















































































          (d)                                                                 (e) 
 
Figure 3.1. Patient A: (a) Picture of TLD placement and (b) through (e) Data comparing 
the calculated dose to TLD measured fractional daily dose at each TLD location. The 







calculated doses are plotted for each TLD and shown in Figures 3.2b-e. 90% of measured TLD 
read lower dose than calculation and 63% of the difference exceeded than 5% at TLD 1 and TLD 
3. A summary of the comparisons is shown in Table 3.3. Dose difference between calculated and 
TLD measured dose for TLD 1 and 3 that were positioned adjacent to each other, exceeded more 
than the standard criteria of 5 % (-5.4 % and -5.2%, respectively). TLD 2 and TLD 4 both agreed 
well, being 3.6% low and 2.4% respectively. 
Table 3.3. Prescribed, calculated, mean TLD measured dose, and Dose difference between 
calculated and measured doses of patient B. 
 
  Prescribed Calculated Measured Differences
  Doses Doses Doses 
TLD fxs [#] fx Dose [cGy] [cGy] N D ± σD  [cGy] Δ ± σΔ [%] 
1 25 200 199.9 15 189.2 ± 9.1 -5.4 ± 4.6 
2 25 200 203.7 15 196.4 ± 5.4 -3.6 ± 2.6 
3 25 200 199.8 15 189.5 ± 5.9 -5.2 ± 3.0 
4 25 200 198 15 193.5 ± 4.6 -2.3 ± 2.3 
 
A summary of the comparison is shown in Table 3.4 where TLDs 1 and 2 had -0.4% dose 
differences between calculated and measured dose and 1.6% and 1.7% differences were observed 
for TLDs 3 and 4, respectively.  
Patient C had 4 packets of TLD taped to surround the scar, one superior, one inferior and 
two laterals (cf. Figure 3.3a). Differences between TLD measured and calculated doses for 
Patient C are plotted for each TLD in Figures 3.3b-e. Small variations in the measured dose were 
observed over the course of treatment, only 3 TLD fraction doses exceeded the calculated dose 
by more than 5%. A summary of the comparisons is shown in Table 3.4 TLDs 1 and 3 were 
positioned adjacent to each other and both agreed well, being 0.2% low and 1.7% high, 






































































































                    (d)                                                   (e) 
 
Figure 3.2. Patient B: (a) Picture of TLD placement and (b) through (e) Data comparing 
the calculated dose to TLD measured fractional daily dose at each TLD location. The 








0.2% low and 1.7% high, respectively. Overall, results are well within the standard criteria for 
delivered dose accuracy of 5%. 
Table 3.4. Prescribed, calculated, mean TLD measured dose, and Dose difference between 
calculated and measured doses of patient C. 
 
  Prescribed Calculated Measured Differences
  Doses Doses Doses 
TLD fxs [#] fx Dose [cGy] [cGy] N D ± σD [cGy] Δ ± σΔ [%] 
1 25 200 200.9 15 200.5 ± 5.6 -0.2 ± 2.8 
2 25 200 202.4 15 201.9 ± 7.3 -0.2 ± 3.6 
3 25 200 201.5 15 204.8 ± 7.0 1.6 ± 3.5 
4 25 200 202.6 15 206.1 ± 5.6 1.7 ± 2.7 
 
Patient D had 4 TLD packets placed to surround the scar as shown in Figure 3.4a. TLD 
measured fractional daily dose at each TLD location were plotted with calculated dose and 
shown in Figure 3.4b-e. 72% of measured TLD exceeded the calculated dose by more than 5%. 
But overall, the variation averaged out and the largest averaged difference out of four TLD 
locations at TLD 1 and 2 were -4.0%.  A summary of the comparison is shown in Table 3.5 
where TLDs 1 and 2 had -4.0% dose differences between calculated and measured dose and 
2.2% and 3.4% differences were observed for TLDs 3 and 4, respectively.  
Patient E had 4 TLD packets placed to surround the scar as shown in Figure 3.5a. Again, 
small variation of the measured dose was observed but 73% of the TLD doses were with within 
5% of the calculated dose. A summary of the comparison between average measured to 
calculated dose is shown in Table 3.6. Difference of each TLD was -0.7%, -2.0%, -2.6%, and -
3.3% for TLD 1, TLD 2, TLD 3, and TLD 4, respectively. 
      B. Impact of air cavity between bolus and the CW 
The percent difference between calculated and measured doses were plotted against air 
cavity size to determine if the values were correlated. Dose differences were compared to both 





































































































                    (d)                     (e) 
 
Figure 3.3. Patient C: (a) Picture of TLD placement and (b) through (e) Data comparing 
the calculated dose to TLD measured fractional daily dose at each TLD location. The 
pink region is the ±5% range about the calculated dose. 
 
 






Table 3.5. Prescribed, calculated, mean TLD measured dose, and Dose difference between 
calculated and measured doses of patient D. 
 
  Prescribed Calculated Measured Differences
  Doses Doses Doses 
TLD fxs [#] fx Dose [cGy] [cGy] N D ± σD [cGy] Δ ± σΔ [%] 
1 25 200 201.2 15 194.1 ± 8.1 -3.5 ± 4.0 
2 25 200 203.6 15 196.0 ± 8.4 -3.7 ± 4.1 
3 25 200 204.5 15 207.3 ± 6.4 1.4 ± 3.1 
4 25 200 205.7 15 210.8 ± 9.3 2.5 ± 4.5 
 
individual TLD location 1-4, and then the percent difference between calculated and measured 
doses were plotted against air gap volume for patient A as shown in Figure 3.6(a)-(b). The slope 
for best-fit linear regression to all the data points for 4 TLD locations were 0.39, 1.1, 1.1, and 
0.54 % cm-3. R-squared values, goodness of fit, were 0.35, 0.16, 0.57, and 0.19. Slope and R-
squared values of all the TLD locations combined result was 0.61 % cm-3 and 0.3. (Figure 3.7b). 
Because the R-square value for all TLD locations combined did not deviate from the individual 
divided data, the rest of the analysis was only done for each patient but not at each TLD location. 
The resulting plots are shown in Figures 3.7 to 3.11. Data for a preliminary TLD patient (Patient 
3, figure 1.6c) whose result showed a downward trend of measured dose as the treatment 
progressed was analyzed as well and shown in Figure 3.12 as patient F and the patient A-E 
combined result is shown in Figure 3.13. The percent dose difference was determined using 
equation (2). 
                                        (2) 
Each patient had 60 data points (15 fractions × 4 dose points/fraction) to correlate the dose 
difference to the air cavity volume and thickness. Best-fit linear regression to all the data points 





















































































         (d)                     (e) 
 
Figure 3.4. Patient D: (a) Picture of TLD placement and (b) through (e) Data comparing 
the calculated dose to TLD measured fractional daily dose at each TLD location. The 










Table 3.6. Prescribed, calculated, mean TLD measured dose, and Dose difference between 
calculated and measured doses of patient E. 
 
  Prescribed Calculated Measured Differences
  Doses Doses Doses 
TLD fxs [#] fx Dose [cGy] [cGy] N D ± σD [cGy] Δ ± σΔ [%] 
1 25 200 200.8 15 199.5 ± 6.4 -0.6 ± 3.2 
2 25 200 203.1 15 199.1 ± 7.7 -2.0 ± 3.8 
3 25 200 201.7 15 196.5 ± 5.8 -2.6 ± 2.9 
4 25 200 200.5 15 193.9 ± 9.3 -3.3 ± 4.7 
 
patient A-E for the better comparison. A summary of the results will be shown and discussed 
later in this chapter. The 95% confidence interval (C.I.) for the regression line is given by 
equation (3). 
                                        (2) 
Each patient had 60 data points (15 fractions × 4 dose points/fraction) to correlate the dose 
difference to the air cavity volume and thickness. Best-fit linear regression to all the data points 
is shown on the plots along with the equation and R-squared value. Scales were kept the same for 
patient A-E for the better comparison. A summary of the results will be shown and discussed 
later in this chapter. The 95% confidence interval (C.I.) for the regression line is given by 
equation (3). 
                                                                                                             (3) 
where  is an equation-derived dose difference [%] value for each air volume and thickness data 
points measured,  is the t-distribution value obtained from excel stastiscal function (TINV), 







































































































         (d)                     (e) 
 
Figure 3.5. Patient E: (a) Picture of TLD placement and (b) through (e) Data comparing 
the calculated dose to TLD measured fractional daily dose at each TLD location. The 








the average air volume or thickness, , value. The C.I. is shown as red lines. The 95% prediction 
interval (P.I.) for the regression line is given by equation (4). 
                                                                                                   (4) 
The P.I. is shown as black dashed lines. Both C.I. and P.I. were calculated with 
Microsoft Excel spreadsheet. 
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    (c)                 (d) 
 
Figure 3.6. Patient A: Dose difference [%] of measured TLD dose and calculated dose versus 























































Figure 3.7. Patient A: (a) Dose difference [%] of measured TLD dose and calculated dose 
versus air cavity volume and (b) Dose difference [%] of measured TLD dose to the calculated 
dose versus air cavity thickness. 
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Figure 3.8. Patient B: (a) Dose difference [%] of measured TLD dose and calculated dose 
versus air cavity volume and (b) Dose difference [%] of measured TLD dose to the calculated 
dose versus air cavity thickness. 
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Figure 3.9. Patient C: (a) Dose difference [%] of measured TLD dose and calculated dose 
versus air cavity volume and (b) Dose difference [%] of measured TLD dose to the calculated 
dose versus air cavity thickness. 
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Figure 3.10. Patient D: (a) Dose difference [%] of measured TLD dose and calculated dose 
versus air cavity volume and (b) Dose difference [%] of measured TLD dose to the calculated 


















































Figure 3.11. Patient E: (a) Dose difference [%] of measured TLD dose and calculated dose 
versus air cavity volume and (b) Dose difference [%] of measured TLD dose to the calculated 
dose versus air cavity thickness. 
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Figure 3.12. Patient F (cf. Fig 1.6c): (a) Dose difference [%] of measured TLD dose and 
calculated dose versus air cavity volume and (b) Dose difference [%] of measured TLD dose and 
calculated dose versus air cavity thickness for previous patient 
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Figure 3.13. Patient A-E: (a) Dose difference [%] of measured TLD dose and calculated dose 
versus air cavity volume and (b) Dose difference [%] of measured TLD dose and calculated dose 





III.   Aim 3 
       A.  TLD Measurements Tests 
1.  Accuracy and Precision of TLD Measurements Due to TLD System 
Three sets of TLD were exposed to known doses (175, 200, and 225 cGy) and were 
treated as unknown sample doses. Calibration TLDs (3 per dose level) were exposed to 100, 150, 
200, and 250 cGy to encompass the sample doses on the same day of sample TLDs delivery with 
the same linac. All TLDs were read the next day, and sample TLD readings were converted into 
dose using the dose calibration. Average measured TLD dose for each of the three “unknown” 
TLD sets was compared to expected dose, as shown in Table 3.7. Differences between measured 
and expected dose were calculated by using the equation (5). 
                                (5) 
These results indicate that the TLD measurement system, used both for in-vivo patient 
dosimetry, as well as phantom measurements in the present study (discussed later in this chapter) 
was accurate to within 2%.  
The precision of a single TLD reading is the standard deviation of the sample of three 
TLDs at each dose level. Expressed as a % (  ), Table 3.6 shows values of 0.8, 1.1, 
and 0.3%, which average 0.7%, the estimated precision of a single TLD dose point. 
Table 3.7. .Expected dose, average TLD measured dose, difference in percentage and their 
standard deviation is shown. 
Expected Dose Avg TLD Dose Difference 
[cGy] [cGy] Δ ± [%] 
175 178.2 ± 1.4 1.8 ± 0.8 
200 198.8 ± 2.2 -0.6 ± 1.1 





2. Accuracy of TLD Dose Measurements in Anthropomorphic CW Phantom 
The accuracy of patient measurements depends primary upon accuracy of TLD system, 
accuracy of TomoTherapy delivery, accuracy of the TomoTherapy treatment planning system, 
intrafraction patient motion, how well the bolus fits the patient, and possibly other patient 
dependent factors. As the present study is designed to evaluate dose inaccuracies due to patient 
effects, the present section looks at dose accuracy without such patient effects. This is done by 
comparing measured with calculated dose for an anthropomorphic CW phantom as shown in 
Figure 3.12. 
 Repeated CW surface dose measurements using the TLD system were taken on the 
anthromorphic CW phantom and compared with treatment planning (TP) calculated dose and 
also planned adaptive (PA) calculated dose. The phantom delivery was performed four times, 
one on one day and three on another. Each day, a single TLD was exposed at each location, and 
there were three readings per TLD, which produces a mean and standard deviation of the mean 
(as in section A).  
After each treatment, the MVCT data was used to perform a Planned Adaptive dose 
calculation for comparison with the measured dose. This allowed the inaccuracy due to 
TomoTherapy delivery to be assessed. TP calculated dose, PA calculated dose, TLD measured 
dose, and percent difference between measured and calculated (both TP and PA). Doses at each 
TLD location (1-4) are shown in Tables 3.8a-d, respectively.  
On day one, the PA calculated dose averaged 3.1% greater than the TP calculated dose. 
On days 2, 3, and 4, the PA calculated dose averaged 0.4% greater, 1.0% lesser, and 0.7% lesser 
than the TP calculated dose. Difference between measured and calculated dose was obtained 
from equation (2). TLD measured dose was consistently higher than both TP and PA calculated 
doses at TLD location 1 and generally lower at TLD location 2, 3, and 4. Calculated and PA dose 
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agreed well to within 3.1%, 0.4%, -1%, and -0.7% average at TLD location 1, 2, 3, and 4, 
respectively. Standard deviation for average difference in TLD measured and calculated dose did 
not exceed more than 2.4 % and 2.7% for average difference between TLD measured and 
planned adaptive dose. This result indicates that our TLD measurements are reliable as they can 
be reproduced to achieve within 2.4% uncertainty. 
 
Figure 3.14. CW anthropomorphic phantom with 4 TLD locations. 
 3.  Film Measurements 
Film measured dose was compared with calculated dose to improve confidence in the 
accuracy of comparison between TLD dose measurements and the calculated dose, and the 
results are shown in Table 3.12. Average TLD measured dose was obtained from 4 repeated 
measurements shown in previous section and was compared with calculated dose. The film 
measurements were repeated twice to obtain uncertainty. Difference between average film 











Table 3.8. (a)-(d) Calculated dose, plan adaptive dose, TLD measured dose, and difference 
between measured and calculated at each TLD location 1 through 4. (e) Summary of the results 





























1 203.8 210.5 219.8 ± 0.2 3.3 7.8 4.4 
1 203.8 210.0 217.8 ± 2.4 3.0 6.9 3.7 
1 203.8 210.5 211.8 ± 1.5 3.0 3.9 0.6 
1 203.8 210.5 216.7 ± 0.9 3.0 6.3 2.9 
Average 3.1 6.2 2.9 
(a) 
 
Table 3.9. (a)-(d) Calculated dose, plan adaptive dose, TLD measured dose, and difference 
between measured and calculated at each TLD location 1 through 4. (e) Summary of the results 





























2 208.8 209.5 196.6 ± 3.5 0.3 -5.8 -6.2 
2 208.8 210.0 206.3 ± 0.6 0.6 -1.2 -1.8 
2 208.8 211.0 204.1 ± 2.2 1.1 -2.3 -3.3 
2 208.8 207.5 208.0 ± 1.1 0.6 -0.4 -3.3 
Average 0.4 -2.4 -3.7 
(b) 
 
Table 3.10. (a)-(d) Calculated dose, plan adaptive dose, TLD measured dose, and difference 
between measured and calculated at each TLD location 1 through 4. (e) Summary of the results 





























3 211.5 209.5 210.6 ± 2.3 -1.0 -0.4 0.5 
3 211.5 209.5 204.7 ± 1.4 -1.0 -3.2 -2.3 
3 211.5 210.5 201.2 ± 9.9 -0.5 -4.9 -4.4 
3 211.5 208.5 199.4 ± 3.4 -1.4 -5.7 -4.4 







Table 3.11. (a)-(d) Calculated dose, plan adaptive dose, TLD measured dose, and difference 
between measured and calculated at each TLD location 1 through 4. (e) Summary of the results 





























4 212.2 211.5 203.0 ± 3.7 -0.3 -4.3 -4.0 
4 212.2 210.0 200.7 ± 2.6 -1.0 -5.4 -4.4 
4 212.2 213.0 211.6 ± 0.6 0.4 -0.3 -0.7 
4 212.2 208.5 204.0 ± 8.0 -1.7 -3.9 -2.2 
Average -0.7 -3.5 -2.8 
(d) 
 
For TLD location 1, 2, 3, and 4, the agreement was excellent with a .  Average dose 
difference between film measured dose and calculated dose was 0.7%, compared for -0.8 % for 
the TLDs but the average standard deviation of the film measurements at 4 different TLD 
location was 0.3 %, compared to 1.1 % for the TLDs, which indicates that the flim measurements 
were more reproducible than the TLD measurements.  Calculated and film measured doses 
agreed to within 3.0 % of each other.   
Table 3.12. Comparison between calculated dose, average film measured dose, dose difference 
between film and calculated and TLD and calculated. ( ). 
TLD location Calc. Dose  
 
[#] [cGy] [cGy] [%] [%] 
1 203.8 210.3 ± 1.5 3.2 ± 0.7 6.2 ± 0.8 
2 208.8 203.8 ± 0.1 -2.4 ± 0.0 -2.4 ± 1.2 
3 211.5 210.2 ± 0.4 -0.6 ± 0.2 -3.6 ± 1.2 
4 212.2 209.9 ± 0.9 -1.1 ± 0.4 -3.5 ± 1.1 
Avg -0.2 ± 0.3 -0.8 ± 1.1 
I
 
B. Impact of Intrafraction Motion 
Result of dose differences between 3 CW treatment deliveries with 3 difference couch 
position at each TLD location are shown in Table 3.9. At TLD locations 1, 2, and 3 couch shift 
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(±1cm) had less than 3.2% difference in the measured dose  when compared to measured dose 
with no couch shift. At TLD location 4, a +1cm couch shift measured 7% less dose than that with 
no shifts. Expect for that TLD reading, 1cm couch shift didn’t have more than 3.2 % difference 
in dose when compared to no shift. The shift of 1cm applied to the couch is 6-7 times larger than 
the largest ant-post displacement (0.15cm) seen in the patient 4DCT data, thus the effect we 
would expect to see from our patient data should be  much smaller and insignificant. 
Table 3.13. Comparison of TLD measured dose between 3 different couch position at each TLD 
location. Δ(-1cm-0cm)/Δ(+1cm-0cm) indicate difference in dose between no couch shift delivery 
















[#] [cGy] [cGy] [cGy] [%] [cGy] [%] 
1 203.8 212.1 210.5 -0.8 205.6 -3.1 
2 208.8 204.2 203.2 -0.5 197.6 -3.2 
3 211.5 211.5 207.4 -1.9 213.9 1.1 
4 212.2 212.2 207.8 -2.1 197.4 -7.0 
Avg -1.3 Avg -3.1 
  
      C. Impact of Foam Cavity Between Bolus and the Phantom Surface 
 The CW phantom was used to measure the surface dose with foam packing material, 
whose density was 15 times that of air, placed between the phantom and bolus. Plots of dose 
difference [%] of measured TLD dose and calculated dose versus foam gap volume and 
thickness are shown in Figure 3.13. Measurements were taken at 4 TLD locations and the 
thickness of foam gap was varied from 0 mm to 18 mm in increments of 3mm. A total of 28 data 
points were collected and used to correlate the dose difference to the volume (25 cm2 × 
thickness) and thickness. Best-fit linear regression slope with its equation and R-square values 
are shown on the plot. The 95% C.I. and P.I. are also shown on the plot. 
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 A summary of the results comparing best-fit values, 95% C.I., and goodness of fit for 
volume and thickness analysis of the patients and phantom is shown in Table 3.10. For the 5 
patients data, dose difference (%) increased as air volume and thickness between the bolus and 
CW increased. The constants of proportionality varied significantly, ranging from 0.0 ± 0.3 to 
0.6 ± 0.1 % cm-3 for the volume analysis and -3.0 ± 4.4 to 9.6 ± 3.0 % cm-1for thickness analysis. 
For the previous patient F, the constants of proportionality were 2.5 ± 0.4 % cm-3 and 23 ± 6 % 
cm-1 , respectively, approximately a factor of 10 greater than values for patient A-E. Reasons for 
their differences are unknown. Contrastingly, for the CW phantom the constant of 
proportionality were 0.07 ± 0.04 % cm-3  and 1.8 ± 1.0 % cm-1 , not inconsistent with data for 
patient A-E. As expected with theory of electron disequilibrium, having air cavity above the 
target would lead to underdosing of the surface dose. Mean slope value obtained from patients 
A-E volume analysis data was 0.3 % cm-3 and 0.07 % cm-3 for the phantom. Mean slope value of 
thickness analysis for the patients was 2.9 % cm-1 and 1.8 % cm-1 for phantom data. However, R2 
values which indicates goodness of fit were extremely small for Patient A-E, averaging 0.1 for 
both volume and thickness analysis, and 0.12 for phantom data. Patient F showed the best R2 
value of 0.71 and 0.51 for volume and thickness, respectively, most likely due to the small 
number of data points collected compared to 5 patients and phantom study. Our extremely small 
































































Figure 3.15. CW Phantom: (a) Dose difference [%] of measured TLD dose and  calculated 
dose versus foam gap volume and (b) Dose difference [%] of measured TLD dose and calculated 




Table 3.14. Summary of the results comparing best-fit values, 95% C.I., and goodness of fit for 
volume and thickness analysis of the patients and phantom 
Patient Patient Patient Patient Patient Patient CW
A B C D E F Phantom
Best-fit values
slope [% cm-3] 0.61 ± 0.12 0.45 ± 0.38 -0.024 ± 0.26 0.41 ± 0.15 0.23 ± 0.13 2.5± 0.44 0.073 ± 0.038
   Y-intercept when X=0.0 -5.0  ± 1.1 3.5 ± 0.6 -0.71 ± 0.53 -0.41 ± 0.76 0.38 ± 0.87 5.1 ± 1.2 0.23 ± 1.0
   X-intercept when Y=0.0 8.3 -7.7 -29.8 1 -1.7 -2.1 -3.2
   1/slope 1.6 2.2 -42.2 2.5 4.4 0.41 13.8
95% Confidence Intervals
   Slope [% cm-3] 0.36 to 0.85 -0.30 to 1.20 -0.54 to 0.49 0.1 to 0.71 -0.027 to 0.48 1.5 to 3.4 -0.006 to 0.023
   Y-intercept when X=0.0 -7.3 to -2.7 2.3 to 4.6 -1.8 to 0.5 -1.9 to 1.1 -1.4 to 2.1 2.6 to 7.6 -1.9 to 2.4
   X-intercept when Y=0.0 6.4 to 10.0 -infinity to -2.1 -infinity to -7.6 to 4.0 - infinity to 3.3 -4.7 to -0.8 -infinity to 15.1
Goodness of Fit
   r^2 0.3 0.02 0 0.11 0.05 0.71 0.12
Patient Patient Patient Patient Patient Patient CW
A B C D E F Phantom
Best-fit values
slope [% cm-1] 9.6 ± 3.0 -3.0 ± 4.4 -1.1 ± 2.9 6.1 ± 1.8 2.7 ± 2.2 22.9 ± 6.2 1.8 ± 1.0
   Y-intercept when X=0.0 -2.5  ± 1.1 1.0 ± 0.7 -0.61 ± 0.53 -0.79 ± 0.75 0.35 ± 1.2 5.7 ± 1.5 0.23 ± 1.0
   X-intercept when Y=0.0 0.26 0.34 -0.56 0.13 -0.13 -0.25 -0.13
   1/slope 0.1 -0.33 -0.91 0.16 0.37 0.04 0.55
95% Confidence Intervals
   Slope [% cm-1] 3.5 to 15.6 -11.8 to 5.8 -6.8 to 4.6 2.5 to 9.8 -1.8 to 7.1 9.5 to 36.4 -0.16 to 3.8
   Y-intercept when X=0.0 -4.8 to -0.22 -0.46 to 2.5 -1.7 to 0.4 -2.3 to 0.72 -2.1 to 2.8 2.4 to 9.1 -1.9 to 2.4
   X-intercept when Y=0.0 0.052 to 0.37 -infinity to -infinity to -0.22 to 0.32 - infinity to 0.33 -0.88 to -0.07 -infinity to 0.60
Goodness of Fit
































I. Response to Hypotheses 
 
The hypothesis tested in this work was that the impact of intrafraction motion on 
TomoTherapy Post-Mastectomy Radiotherapy (PMRT) will be insignificant as (1) the largest 
intrafraction movement of the chest wall (CW) in the medial-lateral, anterior-posterior, and 
superior-inferior dimensions will not exceed 1 cm and (2) that 95% of in-vivo CW point doses 
on the patient surface will be within 5% of calculated dose and all doses within 10% of 
calculated dose.  
The first hypothesis is true as the maximum ant-pos movements of our five patients were 
0.15cm, 0.15cm, 0.11cm, 0.15cm, and 0.06cm respectively. The second hypothesis tested is not 
true due to the following: (1) for all the in-vivo CW point doses acquired on our five patients, 
28% of the measured doses differed from the calculated dose by more than 5% and (2) 2% of all 
data differed from the calculated dose by more than 10%. 
II. Clinical Impact and Clinical Recommendations 
The results of this work indicate differences between TLD measured CW point dose and 
calculated dose, but overall, the fractional variation averaged out and none of the patient’s total 
delivered dose differed from the calculated dose by more than 5%. Air cavities created between 
bolus and the patient’s CW may lead to underdosing of the CW, however, larger number of 
patients data need to be studied before any numerical conclusion can be drawn to predict the 
amount of underdose. It is recommended that the air cavity be kept minimal by waiting until the 
bolus is completely dry before removing it from the patient at the time of fabrication. Proper 
positioning of the bolus to the CW for each treatment fraction should be verified by visual 
observation and evaluation of the positioning MVCT. 
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III. Future Work 
A. Use of MVCT Data to Calculate the CW Dose 
 The present work used kVCT data acquired prior to treatment planning to calculate point 
dose on CW with TomoTherapy TPS. Using fractional MVCT image data to calculate the CW 
dose at each fraction and compare with the measured dose is of interest. Interfraction motion 
cause by anatomical change and/or positioning error could be a factor of discrepancy between 
measured and calculated dose. 
B. Use of Planned Adaptive® Software to Calculate the CW Dose 
 Dose reconstruction, which combines the transmission data taken during the  
treatment with knowledge of the patient’s anatomy and position to calculate the dose delivered to 
each region of the patient is possible with Planned Adaptive® software. (Ruchala et al 1999) 
Comparison between the planned adaptive calculated dose, using the daily MVCT data and the 
measured dose is yet to be studied.  
C. Monte Carlo Calculation of TomoTherapy Delivery 
 TomoTheray TPS uses the convolution/superposition calculation algorithm. Full Monte  
Carlo calculation could be performed to verify the convolution/superposition calculated dose and 
compare the results of the Monte Carlo dose calculation algorithm with measured dose for both 
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Appendix: List of Acronyms 
4DCT: 4 Dimensional CT 
CT: Computed Tomography 
CW: Chest Wall 
DTA: Distance To Agreement 
IGRT: Image-Guided Radiation Therapy 
IMNs: Internal Mammary Nodes 
IMRT: Intensity Modulated Radiation Therapy 
kVCT: kilo-Voltage Computed Tomography 
LINAC: Linear Accelerator 
MBPCC: Mary Bird Perkins Cancer Center 
MLC: Multi Leave Collimator 
MR: Magnetic Resonance 
MSCT: Multi-Slice CT 
MVCT: Mega-Voltage Computed Tomography 
PMRT: Post Mastectomy Radiotherapy 
PTV: Planning Target Volume 
PWTF: Partially Wide Tangent Field 
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RHS: Reverse Hockey Stick 
RPM: Respiratory Gating System 
RT: Radiation Therapy  
sMLC: segmented Multi Leave Collimator 
TLD: Thermoluminescent Dosimeter 
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